Report
EUR 684.00 For Business Accounts Only

Takeda Pharmaceutical Company: FAQ - Leverage Spike Due to ARIAD Acquisition Drives Outlook Change to Negative

CORPORATES ISSUER IN-DEPTH 28 February 2017 RATINGS Takeda Pharmaceutical Company Limited Issuer Rating A1 Outlook Negative Senior Unsecure Rating A1 KEY METRICS: Takeda Pharmaceutical Company Limited FYE 3/2014 FYE 3/2015 FYE 3/2016 Net Sales (Billion) $16.9 $16.3 $15.1 Debt/ EBITDA
Provider
Moody's Investors Service
Moody's Investors Service

Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:

  • 130 countries
    11,000 corporate issuers
    21,000 public finance issuers
    76,000 structured finance obligations



Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.



Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions. 

ResearchPool Subscriptions

Get the most out of your insights

Get in touch